Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

 

AML
17:31

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Navigating the Landscape of Best Frontline Therapies for AML in Older Adults: Midostaurin, CPX-351, Gemtuzumab, Ivosidinib, Glasdegib, Venetoclax

FEATURING Kendra Sweet
  • 50 views
  • January 27, 2020
20:28

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

42 y/o Female With FLT3 + AML: What Should Initial Therapy Be and Is There a Need for Transplant in CR1?

FEATURING Alexander Perl
  • 191 views
  • January 27, 2020
  • 1
16:01

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Should MRD Positivity Guide Therapy in Non-M3 AML? MRD Is Strongly Concordant w/ OS, Negativity May Prove to Be an Endpoint in Future Studies

FEATURING David Sallman
  • 21 views
  • January 27, 2020
23:42

Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies

Should MRD Positivity Guide Therapy in Non-M3 AML? MRD Positivity Is Not Currently Supported by Clinical Evidence

FEATURING Chetasi Talati
  • 21 views
  • January 27, 2020